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Abstract
Purpose To review published data pertaining to the clinical
experience with a dexamethasone intravitreal implant
(Ozurdex®) with a view to establishing a clinically based ther-
apeutic regime.
Methods A PubMed search using theMeSH terms Bretinal vein
occlusion^ and either Bpathophysiology^ or Bdexamethasone
intravitreal implant^ was undertaken for manuscripts published
until August 2015. The analysis included studies involving min-
imally 15 patients under a prospective design or 30 under a
retrospective design, a minimal follow up of 6 months, and at
least 2 intravitreal Ozurdex® injections per eye.
Results In the vast majority of eyes, satisfactory outcomes
were achieved with retreatment intervals of between 3 and
5 months. Initial evidence indicates a similar efficacy com-
pared to anti-VEGF therapies as a first-line treatment. Safety
concerns associated with the long-term and repeated use of
Ozurdex® are not borne out by clinical findings: its implanta-
tion is not associated with a sustained increase in intraocular
pressure (IOP) over time or with the number of applications.
Conclusion Compared with anti-VEGF therapies, the burden
of retreatment is reduced. In patients with chronic macular
edema not responsive to repetitive anti-VEGF therapies, the
outcome after dexamethasone implant treatment is encourag-
ing. However, these results are achieved at the expense of side
effects typically associated with steroids: in up to 20 % of the
Ozurdex®-treated patients, an elevation in IOP, which could
be medically controlled in the majority of cases, and cataract
formation or progression was observed.
Keywords Retinal vein occlusion . Central retinal vein
occlusion . Branch retinal vein occlusion . Pathophysiology .
Dexamethasone . Intravitreal implant .Mead . Copernicus .
Galileo . Geneva . Score . Shasta . Review of literature
Introduction
Within the last 10 years, intravitreal pharmacotherapy has
revolutionized the therapeutic options for macular edema
(ME)-associated retinal vascular diseases, and particularly
for retinal vein occlusion (RVO). Substantial improve-
ments, both visual and morphological, have been achieved
under treatment with anti-VEGF agents and corticoste-
roids. Nevertheless, the efficacy of these intravitreal agents
and their long-term outcome is still evolving. Moreover,
although anti-VEGF agents can elicit a rapid regression
of neovascularization, photocoagulation with a scatter la-
ser still represents the standard of care in the prevention of
extrafoveal neovascular complications whereas it remains
controversial for prophylactic treatment [1]. Data that have
been gleaned from randomized clinical trials regarding
intravitreal therapy with ranibizumab and dexametha-
sone reveal significant functional improvements as com-
pared to those that are achieved solely using laser ther-
apy in the treatment of branch retinal vein occlusion
(BRVO) and central RVO (CRVO). For the treatment
of ME following RVO, intravitreal aflibercept has also
been approved. However, more accurate head-to-head
studies are needed to assess the relative efficacies of
licensed therapies for RVO [2].
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Pathophysiological aspects of the disease
In patients with RVO, ME is the most frequent cause of
visual loss, irrespective of whether the macula is or is not
perfused. If the visual loss that is associated with neovas-
cularization is left untreated, vitreal haemorrhaging, trac-
tional retinal detachment, or neovascular glaucoma can be
expected to ensue in consequence of a breakdown or per-
manent damage to the blood–retinal barrier resulting in
low-grade inflammation and relative ischemia. Therefore,
an increase in the production of VEGF-A is provoked,
which perpetuates vascular leakage and ME [3]. Not sur-
prisingly, VEGF is an effective target for therapeutic inter-
vention in vascular diseases of the retina, including CRVO
[4, 5]. Anti-VEGF therapy has been demonstrated to be
effective in the treatment of CRVO in several clinical
trials, including CRUISE [4], HORIZON [5], GALILEO
[6] and COPERNICUS [7].
The degree of ischemia is correlated with the intravitreal
levels of VEGF and with the prognosis [8]. Angiographically,
it can be classified according to the area of non-perfusion,
nowadays, ideally using ultra-widefield technology [9, 10].
There exists no generally accepted definition for
distinguishing between ischemic and non-ischemic RVO.
However, from a clinical point of view, RVO may be deemed
as non-ischemic (perfused) if fewer than 10 disc areas of non-
perfusion are identified angiographically, which represents
75 % to 80 % of all newly diagnosed CRVO cases. The com-
plete loss of retinal capillaries, with late venous staining in
fluorescein angiography, is indicative of a significant
ischemia-induced up-regulation of VEGF, and is associated
with a high risk for secondary complications. If 10 or more
disc areas of non-perfusion are implicated, then the risk for
neovascularization of the anterior segment is heightened [9,
11]. If in this situation, the vision is good and there is no
relevant ME, then anti-VEGF therapy would not be recom-
mended, but the ischemic areas should be subjected to careful
and, in the early phase, timely observation and eventually
peripheral panretinal laser photocoagulation to avoid the risk
of neovascular complications. It is worthy of note that treat-
ment with an anti-VEGF agent can mask the degree of under-
lying ischemia [1, 2].
Although the mean vitreal levels of VEGF are elevated in
both disease states (CRVO and BRVO), in one-third of the
eyes, these may fall within the normal range despite the pres-
ence of ME [8, 12, 13]. This finding points to the existence of
VEGF-independent pathways that can drive ME and could be
the reason that a fraction of patients is less responsive to anti-
VEGF therapy alone.
RVO is not an isolated retinal vascular disease; choroi-
dal involvement is part of the pathology [14] and pigment
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The dexamethasone-based intravitreal implant
(Ozurdex®)
Ozurdex® is a dexamethasone-bearing vehicle, which has
been developed in the form of a biodegradable intravitreal
implant and which delivers a 700-μg dose of the drug to the
retina and the vitreous. It has been approved for use in the
treatment of RVO-associatedME [24] and non-infectious pos-
terior uveitis [16] by the Federal Office of Food and Drug
Administration in the USA (FDA), by the Commission for
European Medicines Administration (EMA), and by
Swissmedic. Ozurdex® has also been used efficaciously in
the treatment of other clinical conditions including the post-
operative ME that is associated with cataract surgery (Irvine-
Gass syndrome) and vitrectomy, diabetic ME, persistent ME,
intra-ocular inflammation and adjunctively in cases of age-
related macular degeneration [15]. However, randomized clin-
ical trials relating to the use of Ozurdex® in the treatment of
these conditions have as yet not all been completed. Safety
concerns associated to the use of Ozurdex® include the for-
mation or progression of cataracts and a transient increase in
intraocular pressure that peaks after 1 to 2 months, yet is
usually amenable to medical management [15, 17, 18].
Recently, it was shown by aqueous laser flare measure-
ments that the impact of Ozurdex® on recovery of the
uveovascular barrier in eyes with RVO correlates with its ef-
fect on visual acuity and central retinal thickness [19].
Published data appertaining to the effects of steroids
on RVO
In the SCORE study— a multicenter clinical trial— the effi-
cacy and safety of 1-mg and 4-mg doses of preservative-free
intravitreal triamcinolone were assessed in patients with ME
that had developed secondary to perfused CRVO. This study
marked a turning point in the management of RVO, since it was
the first of its kind to report on an effective treatment strategy
for CRVO-associated ME. For BRVO-associated ME, no dif-
ferences in visual acuity were observed between the standard
care (laser treatment) and the triamcinolone-treated groups.
However, the adverse event rates — particularly for rises in
intraocular pressure and the formation or progression of cata-
racts — were higher in the group of BRVO patients that had
been treated with 4-mg doses of triamcinolone than in either the
BRVO-patient group that had received 1-mg doses of the drug
or the standard care one [20, 21].
In the Geneva study — a randomized, controlled, clinical
trial— 1267 patients withME,which had developed secondary
to either CRVO (35 %) or BRVO (65 %), were monitored for
minimally 12 months after treatment with 0.35- and 0.7-mg
doses of dexamethasone [22, 23]. The dexamethasone-treated
eyes manifested significant improvements in visual function in
contrast to the untreated controls, and they sustained a support-
able profile of side effects. A sub-group of 17 patients were
monitored for a minimal follow-up period of 50 months. The
data that were gleaned from these individuals revealed the vi-
sual prognosis to be better in BRVO- than in CRVO-afflicted
eyes. Inmore than 50% of these patients, a cataract progression
was observed. However, a persistent rise in intraocular pressure
was reported in only one case; and, likewise, in one case alone,
neovascularization and vitreal haemorrhaging were apparent.
Hence, treatment with dexamethasone may be deemed safe in
the long run [22, 23]. A limitation of the Geneva study was that
only two injections of dexamethasone at fixed 6-monthly inter-
vals were administered. During the intervening period, the vi-
sual acuity deteriorated and the retinal thickness increased sub-
stantially, owing to the subsidence of drug activity. This prob-
lem was avoided in eyes that underwent anti-VEGF therapy,
since the drug was delivered on a monthly basis in this study
[23]. From the body of data that has been collected to date, it is
now evident that the effects of intravitreally-administered dexa-
methasone can be sustained for 4 months (range: 3 to 7months)
irrespective of the patient’s clinical background. A retreatment
initiation on an as needed basis (PRN regime) would necessi-
tate reinjection intervals of substantially less than 6 months for
the vast majority of eyes [24, 25–27]. Since the recurrence of
retinal edema precedes the functional impairment by 2 weeks,
the decision for reinjection would ideally be based on OCT
criteria [28].
In the Shasta study — a multicenter retrospective clin-
ical trial — 289 patients with CRVO- or BRVO-
associated ME were evaluated after treatment with dexa-
methasone. Two to 9 dexamethasone implants (mean:
3.2) were injected either as the sole therapy (29.1 %) or
in conjunction with other treatment strategies. The mean
duration of the ME prior to the injection of the first
dexamethasone implant was 18.4 months, and the mean
re-injection interval was 5 to 6 months. A best-corrected
visual acuity increase of +1.0 line was attained 4 weeks
after the onset of treatment, and this level was subse-
quently sustained for 20 weeks after the injection of the
final dexamethasone implant. The central retinal thick-
ness decreased significantly compared to the baseline
level (P ≤ 0.037) and a best-corrected visual acuity in-
crease of≥ 2 lines was achieved in 66.7 % of the patients
with CRVO and in 59.7 % of those with BRVO. In
32.6 % of the CRVO- and BRVO-afflicted eyes, an in-
traocular pressure increase of≥ 10 mm Hg was reported.
In 29.1 % of the patients, intraocular pressure-lowering
medication was administered, and in 1.7 %, incisional
glaucoma surgery was called for. In this study, a larger
cohort of RVO patients receiving more than two
dexamethasone-bearing implants was assessed than here-
tofore, and no new safety concerns were identified as a
consequence of the multiple injections [29, 30]. In an
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earlier published retrospective assessment of 33 RVO-
afflicted eyes, re-treatment with dexamethasone was nec-
essary 4.7 ± 1.1 months after the first injection and 5.1
± 1.5 months after the second in order to sustain a sig-
nificant improvement in the best-corrected visual acuity
and in the central retinal thickness. No side effects other
than those to be expected after the intraocular adminis-
tration of corticosteroids were revealed [31]. Functional
improvements were evident already after the 1st month
of treatment with dexamethasone, and were thereafter
sustained until the end of the 3rd month; but from the
4th month onward, they were lost. The repeated injection
of dexamethasone over a time course exceeding
12 months is deemed to be a safe procedure, even though
it is associated with accelerated cataract progression and
rises in intraocular pressure which, nevertheless, can usu-
ally be brought under control by medical management
[26, 32]. In a retrospective study involving a consecutive
series of 51 eyes of 49 patients with RVO-associated
ME, 70 % of the individuals responded to injections of
dexamethasone implants with an improvement in visual
acuity and a recession in ME within 3 months of treat-
ment, and in 30 % of the eyes, the gain in visual acuity
was ≥15 letters. In 56 % of the patients, a relapse was
observed after a median follow-up time of 17 to
18 weeks, and re-injections of dexamethasone were re-
quired to restore the gains in visual acuity. However, in
some of the eyes, the duration of the positive response to
treatment was curtailed to 10 weeks. In 27 % of the eyes,
the rises in intraocular pressure needed to be medically
controlled, and in 5 %, neovascular complications devel-
oped [24]. The findings appertaining to rises in intraoc-
ular pressure accord well with the data that are presented
in another study, which involved the retrospective analy-
sis of 342 RVO-afflicted eyes, that had been monitored
for 8 months after treatment with intravitreal injections of
dexamethasone [33]. In 20 % of the eyes, the intraocular
pressure increased; in 9 %, it rose by more than 10 mm
Hg above the baseline level, but in only 2 % did the rise
exceed 35 mm Hg. Eyes in which a pre-existing
glaucomatous condition had been identified were not
more prone to increases in intraocular pressure than were
those in which no such state had been registered. During
the 8-month follow-up period, 1.5 % of the eyes required
cataract surgery. No correlation has been observed be-
tween the number of dexamethasone injections, neither
the time interval to re-injection, nor rises in intraocular
pressure. Hence, it is unclear why the increases in intra-
ocular pressure were less pronounced in the aforemen-
tioned German study [33] than in the North American
Shasta trial [29, 30]. So, the findings of the latter study
are more akin to those that have been reported for sim-
ilarly afflicted eyes in Switzerland.
Two case studies in which anti-VEGF- and dexamethasone-
based therapies were combined have been reported [34, 35]. In
one of these— a retrospective interventional study— 33 RVO-
afflicted eyes were intravitreally injected either with
ranibizumab and then with dexamethasone, or with dexameth-
asone alone. The visual gains were more marked and were
achieved more rapidly in the former than in the latter group
[34]. In another prospective study, 34 RVO-afflicted eyes were
intravitreally injected either with a combination of bevacizumab
and dexamethasone, or with dexamethasone alone. The com-
bined therapeutic regime proved to be more efficacious than the
mono-therapeutic one with increase in visual acuity and reduc-
tion of central retinal thickness. The visual gains that were
achieved persisted for longer periods of time [35]. This confirms
the results of the Shasta trial in which combination therapy
showed an extended duration of effect under Ozurdex if com-
bined with anti-VEGF drugs. The risk of an increased IOP was
higher in the combination therapy group, which may at least
partially be explained by a selection bias [30].
Though the possibility of tachyphylaxis after repeated in-
jections of intraocular corticosteroids has, meanwhile, been
discussed for a decade [24, 36, 37], there is still no evidence
for its existence after repeated use of intravitreal corticoste-
roids [26, 38, 39]. A rebound phenomenon, in contrast to
tachyphylaxis, representing a more pronounced macular ede-
ma after loss of therapeutic effect has been reported [32, 40]
and seems to be similar to that after repeated anti-VEGF in-
jections in RVO [41, 42].
The efficacy of dexamethasone implants in cases with re-
fractory macular edema under anti-VEGF therapy for retinal
vascular disorders has been demonstrated [43]. Nevertheless,
eyes pre-treated with anti-VEGF drugs, i.e. bevacizumab,
seem to respond anatomically equally well to an additional
therapy with triamcinolone or dexamethasone, although this
does not obviously go along with an additional gain in visual
function compared to the one in treatment-naïve eyes. The
former, however, is prone to a more pronounced effect on
the IOP of affected eyes, whereas the latter showed a moder-
ately longer duration of effect [44].
The dexamethasone implant may be as effective as
ranibizumab in treatment-naïve eyes with vision loss due
to RVO [45, 46], requiring less injections for the well-
known price of a medically well-controlled rise in IOP of
more than 5 mmHg and cataract progression in nearly half
of the eyes. On the other hand, change of treatment is less
likely required after intravitreal dexamethasone than after
anti-VEGF therapy [30, 47–50]. The dexamethasone implant
may be used in cases in which the role of anti-VEGF agents
has not been equally established, namely in ischemic reti-
nopathies: its positive — though due to the ischaemic state,
functionally limited — effect over 12 months in ischaemic
RVO has prospectively been demonstrated [51, 52]. In indi-
viduals younger than 50 years with 50 % experiencing a
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three-line improvement in visual acuity with a mean of 1.8
implantations over 12 months was achieved. This is worth
mentioning because these patients comprise the working-age
group suffering mostly from the economic burden of fre-
quent controls and reinjections [53].
Finally, the risk of complications, namely of an increase of
IOP, does peak at 1 to 2 months after first treatment. Thereafter,
no rise over time or with the number of injections was reported,
although patients with pre-existing ocular hypertension and
glaucoma may be exposed to a higher risk. An initial control
of IOP will be needed within 4 weeks after implantation. Phakic
patients have to expect cataract progression with the need of
cataract surgery within roughly 1 year [54, 55].
As a therapeutic weapon against ME of various aetiologies,
dexamethasone is assuming an increasingly elevated rank in the
clinical arsenal, owing to its potency, the dose-consistency, the
prolonged duration of action, and, compared to other corticoste-
roids, its favourable safety profile. However, few available pro-
spective head-to-head comparisons and combinations with other
treatment modalities allow as of yet one to precisely define the
role of dexamethasone in clinical practice [15] (Table 1).
Conclusion
To achieve satisfactory visual and anatomic outcomes after
the intravitreal administration of dexamethasone implants, the
re-injection interval needs to be considerably less than
6 months in many instances. To date, there are no indications
that the long-term use of dexamethasone poses a safety haz-
ard. Further evidence appertaining thereto has been recently
furnished by a phase III trial (MEAD) in which diabetic ME
was treated with intravitreal injections of dexamethasone im-
plants. The findings revealed the lack of correlation between
dexamethasone treatments per se and intermittent increases in
intraocular pressure, or between the number of dexametha-
sone injections and rises in intraocular pressure per se [56]. In
existing head-to-head trials in which the effects of anti-VEGF
agents and dexamethasone have been directly compared, the
interval of 6 months was, according to more recent experi-
ence, too protracted for the sustenance of the therapeutic ef-
fect, which can be maintained for approximately 4 months.
Published reports in which re-injections have been made
after shorter intervals on an Bas needed^ basis are now
available [26, 32]. Compared to anti-VEGF therapies, the
burden of re-treatment is reduced. And in cases of chronic
ME that are refractive to repeated anti-VEGF therapy, the
response to dexamethasone is good. The future will reveal
whether an early combined treatment strategy involving an
anti-VEGF agent and dexamethasone elicits superior results
to those that can be achieved using either of these drugs
alone in terms of a long-term compensation of the underly-
ing impaired vascular situation [34, 35].
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